Abbott Laboratories (ABT) — Fair Value Analysis

Base-case fair value (P50): $113.08 · Current price: $112.68 · Verdict: Fairly Valued

The Verdict on ABT

Abbott Laboratories (ABT) is currently trading at $112.68. Our comprehensive Monte Carlo simulations, which model thousands of potential forward scenarios, establish a median fair value (P50) of $113.08. This rigorous analysis leads to a "Fairly Valued" verdict for ABT, indicating that its current market price closely aligns with our central estimate of intrinsic worth. The slight +0.4% difference between the current price and our P50 fair value suggests the market is effectively pricing in ABT's operational and financial prospects as of now. This outcome points to a balanced assessment, where neither significant overvaluation nor undervaluation is evident based on our quantitative models.

How ABT stacks up against Healthcare

Within the dynamic Healthcare sector, Abbott Laboratories maintains an "average" quality tier when assessed against its industry peers. This designation reflects its operational and financial health, suggesting a stable but not exceptional standing within the sector. The fact that ABT’s $112.68 is in close proximity to our $113.08 fair value estimate further reinforces this "average" quality assessment. The market, in pricing ABT at its current level with a +0.4% difference to our median fair value, appears to be appropriately reflecting its sector-standard performance and risk profile, without implying significant mispricing relative to its fundamental characteristics.

What this means for investors

For investors evaluating Abbott Laboratories, the "Fairly Valued" verdict, with a median fair value of $113.08 against a $112.68, suggests a relatively neutral investment outlook from a pure valuation perspective. The nominal +0.4% indicates limited immediate upside potential based on our P50 estimate, while also implying that substantial overvaluation is not currently a primary concern. Given ABT's "average" quality tier within the Healthcare sector, investors prioritizing value might find the stock appropriately priced. Those seeking significant alpha may look for opportunities with a more compelling valuation gap. For a deeper dive into the full range of possibilities, including specific downside and bull case scenarios, sign up for a free FairCurve account to access the complete Monte Carlo distribution and track ABT's fair value as new financial data is released.